Ketamine in Severe Traumatic Brain Injury

This early Phase I interventional trial (n=10) will assess the neurophysiological effect of ketamine in patients with severe Traumatic Brain Injury (TBI).

Traditionally, ketamine has been considered contraindicated due to concerns about elevated intracranial pressure (ICP), but new data challenges this assumption. This study aims to characterise the response to a single dose of ketamine in critically ill TBI patients with ICP and brain tissue oxygenation (PbtO2) monitoring. The primary outcome measures will include intracranial pressure and brain tissue oxygenation levels, measured within 3 hours post-administration.

Participants must be aged 18 or above and have severe TBI with intracranial monitors in place. Exclusion criteria include documented allergy to ketamine, certain cardiac conditions, and elevated ICP or low PbtO2 levels.

The study, sponsored by the University of Texas Southwestern Medical Center, is expected to start in February 2024 and complete by November 2024.

Topic Traumatic Brain Injury
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Texas
The University of Texas is conducting research with psychedelics across locations in Houston, Austin, Dallas and San Antonio.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.